Synthetic Biologics Inc., of Rockville, Md., said it closed a its underwritten public offering of 13.225 million shares of its common stock, including a fully exercised over-allotment option by the underwriters covering 1,725,000 shares, offered at a price of $1 per share. The gross proceeds were $13.2 million.